Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Waldhauer · SciRah

Researcher profile · Semantic Scholar

I. Waldhauer

Share profile

I. Waldhauer — researcher profile on SciRah

h-index: 19
Works: 49
Citations: 4,432

Most-cited papers

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
C. Ferrara, Sandra Grau, C. Jäger, P. Sondermann +8 more
2011Proceedings of the National Academy of Sciences of the United States of America790 citations Open access
Semantic Scholar
NK cells and cancer immunosurveillance
I. Waldhauer, A. Steinle
2008Oncogene681 citations Open access
Semantic Scholar
Tumor-associated MICA is shed by ADAM proteases.
I. Waldhauer, Dennis Goehlsdorf, F. Gieseke, T. Weinschenk +5 more
2008Cancer Research390 citations Open access
Semantic Scholar
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
S. Herter, F. Herting, O. Mundigl, I. Waldhauer +18 more
2013Molecular Cancer Therapeutics352 citations
Semantic Scholar
Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction
S. Welte, Sabrina Kuttruff, I. Waldhauer, A. Steinle
2006Nature Immunology266 citations
Semantic Scholar
Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
I. Waldhauer, A. Steinle
2006Cancer Research254 citations Open access
Semantic Scholar
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Laura Codarri Deak, V. Nicolini, Masao Hashimoto, M. Karagianni +31 more
2022Nature247 citations Open access
Semantic Scholar
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
C. Klein, I. Waldhauer, V. Nicolini, A. Freimoser-Grundschober +26 more
2017Oncoimmunology245 citations Open access
Semantic Scholar
TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann +4 more
2006208 citations
Semantic Scholar
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
L. Peterson, C. J. Bell, S. Howlett, M. Pekalski +12 more
2018Journal of Autoimmunity138 citations Open access
Semantic Scholar
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann +4 more
2006Brain : a journal of neurology138 citations
Semantic Scholar
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
S. Herter, L. Morra, Ramona Schlenker, J. Šulcová +9 more
2016Cancer Immunology and Immunotherapy132 citations Open access
Semantic Scholar
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
P. Brünker, K. Wartha, T. Friess, Sandra Grau-Richards +23 more
2016Molecular Cancer Therapeutics112 citations Open access
Semantic Scholar
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
I. Waldhauer, V. Gonzalez‐Nicolini, A. Freimoser-Grundschober, T. Nayak +25 more
2021mAbs106 citations Open access
Semantic Scholar
Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti–Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis
P. Laverman, T. van der Geest, Samantha Y. A. Terry, Danny Gerrits +12 more
2015Journal of Nuclear Medicine93 citations Open access
Semantic Scholar
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
C. J. Bell, Yong-Liang Sun, U. Nowak, Jan Clark +12 more
2015Journal of Autoimmunity85 citations Open access
Semantic Scholar
Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).
M. M. Soerensen, W. Ros, M. Rodriguez Ruiz, D. Robbrecht +13 more
201837 citations
Semantic Scholar
A novel EGFRvIII-T cell bispecific antibody for the treatment of glioblastoma.
R. Iurlaro, I. Waldhauer, E. Planas-Rigol, Ester Bonfill-Teixidor +31 more
2022Molecular Cancer Therapeutics29 citations Open access
Semantic Scholar
Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer
I. Waldhauer, V. Nicolini, C. Dunn, A. Freimoser-Grundschober +20 more
201319 citations
Semantic Scholar
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure
A. Spreafico, E. M. Couselo, A. Irmisch, J. Bessa +19 more
2024Frontiers in Oncology17 citations Open access
Semantic Scholar
Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration
Arthur J. Van De Vyver, A. Walz, M. Heins, A. Abdolzade-Bavil +3 more
2022Frontiers in Pharmacology14 citations Open access
Semantic Scholar
Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab
S. Herter, I. Waldhauer, T. Otz, F. Herting +10 more
20109 citations
Semantic Scholar
TGF-b and metalloproteinases differentially suppress NKG 2 D ligand surface expression on malignant glioma cells
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann +4 more
20069 citations
Semantic Scholar
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs
O. Abdelmotaleb, A. Schneider, I. Waldhauer, Johannes Sam +14 more
2025mAbs8 citations Open access
Semantic Scholar
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
V. Gonzalez‐Nicolini, S. Herter, Sabine Lang, I. Waldhauer +7 more
2015Clinical Cancer Research8 citations
Semantic Scholar
Abstract LB-389: Combination of TYRP1-TCB, a novel T cell bispecific antibody for the treatment of melanoma, with immunomodulatory agents
V. Nicolini, I. Waldhauer, A. Freimoser-Grundschober, M. Richard +14 more
2020Bioinformatics, Convergence Science, and Systems Biology7 citations
Semantic Scholar
Abstract 486: Tumor-targeted, engineered IL-2 variant (IL-2v)-based immunocytokines for the immunotherapy of cancer.
C. Klein, I. Waldhauer, V. Nicolini, C. Dunn +24 more
20136 citations
Semantic Scholar
Abstract 1552: A novel PD1-IL2v immunocytokine for preferentialcis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
C. Klein, Laura Codarri-Deak, V. Nicolini, S. Seeber +14 more
2019Immunology5 citations
Semantic Scholar
Abstract 2217: Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade
G. NicoliniValeria, I. Waldhauer, A. Freimoser-Grundschober, S. Evers +5 more
20165 citations
Semantic Scholar
Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1
Javier Sánchez, V. Nicolini, Linda Fahrni, I. Waldhauer +8 more
2022AAPS Journal4 citations
Semantic Scholar
Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1
P. Umaña, L. C. Deak, Masao Hashimoto, R. Ahmed +22 more
20214 citations Open access
Semantic Scholar
Abstract 3629: Engineering a novel asymmetric head-to-tail 2+1 T-cell bispecific (2+1 TCB) IgG antibody platform with superior T-cell killing compared to 1+1 asymmetric TCBs
C. Klein, C. Neumann, T. Fauti, Tina Weinzierl +18 more
20173 citations
Semantic Scholar
Abstract LB-236: M4-3-ML2, a novel glycoengineered humanized IgG1 antibody, targeting a membrane-proximal epitope of MCSP/CSPG4 exhibits potent ADCC inductionin vitroandin vivoanti-tumoral efficacy in disseminated melanoma models
Ekkehard Mössner, Gérald Tuffin, S. Colombetti, Olivier Freytag +18 more
20123 citations
Semantic Scholar
Vascularized tumor organoids enable immunotherapy testing in tumor-remodeled stroma
Reiner Wimmer, Rok Krese, Louisa Henniger, Steve Niu +10 more
2026bioRxiv2 citations Open access
Semantic Scholar
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
James R. Whittle, M. Vieito, K. Rohrberg, M. Rodriguez Ruiz +24 more
2025Neuro-Oncology Advances2 citations Open access
Semantic Scholar
Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodies in vitro and in vivo
G. NicoliniValeria, I. Waldhauer, A. Freimoser, S. Colombetti +5 more
20142 citations
Semantic Scholar
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII.
Elisabeth Husar, Silke Simon, Afsaneh Abdolzade-Bavil, A. Augustin +15 more
2025Journal of Pharmacy and Science1 citations
Semantic Scholar
Abstract 1235: Impact of anti-CD3 and tumor-target binder affinities on in-vitro potency, in-vivo efficacy, and cytokine release
O. Abdelmotaleb, A. Schneider, Thomas Hofer, Johannes Sam +10 more
2024Cancer Research1 citations
Semantic Scholar
Abstract 2774: The triple combination of the FAP-IL2v immunocytokine with PD-L1 checkpoint inhibitory and CD40 agonistic antibodies results in long-term tumor control in the orthotopic PancO2 model
V. Nicolini, I. Waldhauer, A. Freimoser, Emily Corse +3 more
2018Immunology1 citations
Semantic Scholar
Abstract 2027: Novel 3D tumor-immune cell spheroid models for assessment of cancer immunotherapy agents
L. Morra, I. Waldhauer, C. Klein, P. Umaña +1 more
20141 citations
Semantic Scholar
Abstract LB-264: Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics.
I. Waldhauer, L. Morra, Steffi Lehmann, I. Agarkova +5 more
20131 citations
Semantic Scholar
Early functional reactivity to a CEACAM5 x CD3 T cell bispecific antibody in solid tumors associates with baseline immune contexture rather than target antigen density alone
Sabine Wilson, Abraham Silva, M. Serrano-Serrano, V. Karanikas +8 more
2026npj Precision Oncology0 citations Open access
Semantic Scholar
P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response
O. Abdelmotaleb, C. Klein, I. Waldhauer, J. Sam +9 more
2025Poster Presentations0 citations Open access
Semantic Scholar
Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1
Javier Sánchez, V. Nicolini, Linda Fahrni, I. Waldhauer +8 more
2023AAPS Journal0 citations Open access
Semantic Scholar
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
L. C. Deak, C. Klein, Laura Lauener, S. Seeber +2 more
20180 citations
Semantic Scholar
Crystal structure of a interleukin-2 variant in complex with interleukin-2 receptor
C. Klein, A. Freimoser-Grundschober, I. Waldhauer, M. Stihle +2 more
20170 citations
Semantic Scholar
Abstract 1594: Enhancement of the anti-tumor activity of CEA TCB via combination with checkpoint blockade by PD-L1 and interleukin-2 variant immunocytokine
M. Bacac, S. Colombetti, Linda Fahrni, T. Fauti +10 more
20170 citations
Semantic Scholar
Abstract 2955: Herceptarg, a novel heterodimeric biparatopic common light chain IgG1 antibody based on trastuzumab and pertuzumab, exerts potent anti-tumoral activity
E. Moessner, U. HoferThomas, I. Waldhauer, W. Scheuer +11 more
20160 citations
Semantic Scholar
Proteolytic shedding of NKG2D ligands from tumour cells
I. Waldhauer
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Umaña×31
Invite
P. Umaña — researcher profile on SciRah
C. Klein×27
Invite
C. Klein — researcher profile on SciRah
M. Bacac×22
Invite
M. Bacac — researcher profile on SciRah
A. Freimoser-Grundschober×19
Invite
A. Freimoser-Grundschober — researcher profile on SciRah

×14

Invite

V. Nicolini — researcher profile on SciRah

Invite

S. Herter — researcher profile on SciRah

Invite

C. Gerdes — researcher profile on SciRah

S. Colombetti×11

Invite

S. Colombetti — researcher profile on SciRah

Johannes Sam×10

Invite

Johannes Sam — researcher profile on SciRah

Erwin van Puijenbroek×9

Invite

Erwin van Puijenbroek — researcher profile on SciRah

Invite

E. Moessner — researcher profile on SciRah

Invite

R. Hosse — researcher profile on SciRah